Latest Drugwonks' Blog
My article can be found here.
Yesterday, Brian Sullivan of Fox Business News blogged on a similar idea. His blog can be found here.
Today, Brian and Degan McDowell and I discussed the idea on air. My point is that, when it comes to healthcare reform, we seem to be discussing everything except diet and exercise ... and personal responsibility.
We talked about tax incentives (the "carrot") as well as the political time bomb of a fat VAT (the "stick").
All things considered -- a very timely conversation.
The complete video interview can be found here.
As Julia Child would say: "Bon Appetit!"
Read full article here.
"Section 3105 of the Kennedy bill says American health Benefit Gateways would be created in every state, serving as a health insurance exchange. A "Navigators" program would award grants to public and private entities to "conduct public education; distribute fair and impartial information regarding health plans; [and] assist with enrollment and provide information that is culturally and linguistically appropriate for the population." The bill stipulates that both health insurance issuers and current independent insurance agents would be prohibited from participating in the Navigators program."
Read more here.
And here is what ACORN is already doing:
"Moving toward maximum eligible participation in federal and state benefits programs is one of ACORN’s key national priorities. ACORN will begin transitioning many of its offices to the Nets2Ladders screening platform (Nets2Ladders is also a key strategic partner with H&R Block). Nets2Ladders offers a powerful, automated benefits enrollment platform that will increase the efficiency and effectiveness of enrolling low-income families in federal and state benefits programs. This software integrates tax return and benefit information so that the information that is collected while filing the tax return is automatically updated into the benefits screening tools, reducing the amount of time needed to add a benefit screening component. Beginning in January 2008, ACORN will conduct benefits screening and enrollment in approximately 26 states, meaning that anyone visiting an ACORN Tax and Benefits Access Center in these states can also quickly be screened for up to 15 federal, state, and local assistance programs, including:
• Food Stamps
• Medicaid
Insurance Program (SCHIP)
ACORN’s new screening platform will generate complete applications that are then printed out for clients, saving them countless hours of trouble and heartache and more importantly dramatically increasing their chances for actually qualifying for these important programs. By January 2010, all 50 states will be covered by the ACORN screening and enrollment platform"
Read more here
Will Congress ban ACORN and other politically-motivated groups from grabbing control of health care at the grass roots level with federal funding?
Exchanges we can believe in....
President Obama's effots to sell lawmakers and the American public on the merits of his proposals have been hamstrung by his preference for a big-government solution to the nation’s healthcare woes. While it’s true that reform is needed, there’s no need to completely remake the health sector. Instead, the president should borrow from more hands-off reforms, like Medicare Part D, which have been both successful and popular in the past.
A recent survey revealed that 92 percent of beneficiaries were satisfied with their drug coverage in 2008. And, at last tally, Part D was costing about 30 percent less than initial budget projections. The program’s popularity as well as its cost-effectiveness can be attributed in large part to its use of the private-sector competition.
Part D allows Medicare participants to choose from a variety of government-subsidized yet privately-administered drug plans. Seniors get to choose from a number of plans and decide for themselves which one best suits them. Meanwhile, insurers must compete to offer high-quality plans at reasonable prices.
But does Part D really work? The numbers speak for themselves: in 2004 nearly one in four seniors lacked drug coverage. By 2006, when Part D took effect, that statistic dropped to seven percent.
Democratic lawmakers could use this success as a roadmap for expanding coverage while avoiding the kind of drastic government intervention that inspired such rancor in opponents of the public option.
In other words, create a program that allows insurers to compete to offer those 8-16 million chronically uninsured Americans the best plan. The government could then provide subsidies to make that plan even more affordable. This would by no means be easy to implement. But it wouldn’t be revolutionary either, since the policy’s basic framework has already proven to work well.
President Obama is in desperate need of fiscally responsible healthcare reform ideas. A Part D-like insurance program might be exactly what he’s looking for.
For more on this, see a new article in Reuters' "Great Debate" series here.
Congressman Boustany has an insightful take on health care reform and explained some of his ideas to us in this video interview.
But his attempt to create an atmosphere of bipartisan support evaporated with the turn of a single phrase:
“I will not stand by while the special interests use the same old tactics to keep things exactly the way they are. If you misrepresent what’s in the plan, we will call you out.”
Threats to those who honestly oppose his ideas? Or does that also apply to those (such as Speaker Pelosi) who accused our fellow citizens of being “anti-American” for venting their honest frustrations at town hall meetings?
No question this speech was largely an exercise about reasserting the President’s leadership. Did that happen? Will, for example, Henry Waxman decide that he is now obligated to the agreements the President reached with, among others, PhRMA? If Mr. Waxman remains unobligated, will the President “stand by” or will he “call him out.”
“If you like your healthcare plan, you can keep it.” But “your healthcare plan” could be more expensive – or your employer may cease to offer it at all. As the old Yiddish proverb goes, “A half-truth is a whole lie.”
And as far as the tax on “gold-plated” insurance policies, here’s what Robert Pear wrote in the New York Times, “Proponents say the idea … would encourage employers to buy cheaper, less generous coverage for employees, thereby reducing excessive use of medical services.”
“Excessive use?” According to whom? And what does “gold-plated” mean? No details offered.
Pear continues, “But many House Democrats and labor union leaders have resisted those proposals, saying the tax would often be passed on to employers and to workers in the form of higher premiums” and “that could be seen as violating a campaign promise not to raise taxes on anyone making less than $250,000 a year."
The President’s for a “not for profit” public plan – but “We should remain open to other ideas that accomplish our ultimate goal.” Translation: “I’ll sign a bill without a public plan.”
And the left cringes.
Welcome news that the President supports a yet-to-be written initiative to create pilot projects intended to curb medical malpractice lawsuits. But who will co-pilot this idea in Congress. That’ll be interesting to see -- or to see if it really happens.
Strangely lacking – a timeline, or even a call for one.
As Senator John McCain commented post-speech on the Larry King Show, “Facts are stubborn things.”
Here’s what Stephen J. Ubl, president and CEO of the Advanced Medical Technology Association (AdvaMed), had to say in response to the proposed $40 billion tax on medical devices and diagnostics that is included in a draft health care reform proposal from Senator Max Baucus, chairman of the Senate Finance Committee:
“This tax will raise the cost of care for all patients, especially those in greatest need of advanced treatments and diagnostics. It is a form of double taxation, since a portion of the hundreds of billions in cuts aimed at our customers, including hospitals, nursing homes, and home health care agencies will be passed on to us. Moreover, the tax will fall most heavily on the small and emerging companies that are the backbone of our industry, often driving development of cutting-edge treatments and cures, and are least able to pay new taxes. Additionally, the fee imposed on clinical labs raises serious concerns in view of other cuts to payments for lab services.”
“While AdvaMed supports broad-based health care reform and has been working to achieve that important goal, we cannot support a proposal that unfairly singles out the medical technology industry for a tax on innovation on top of the billions in cuts that the industry would already have to absorb within the health care reform proposal. We will continue to work with congressional leaders and the White House to further real health reform and to eliminate this counterproductive proposal from any reform package considered by the Congress.”
Real reform doesn't pay for itself by standing on the throat of innovation.
FDA may hold approval of supplemental indications to a higher standard of evidence than what can feasibly be obtained since the drugs are already available to treat patients in an off-label setting, FDA Office of Drug Oncology Products Director Richard Pazdur indicated at a Sept. 1 advisory committee meeting.
ODAC was convinced that clofarabine is active in getting elderly AML patients into remission, but ultimately voted 9-3 that the additional trial did need to be conducted prior to its approval - regardless of the enormous disease and patient population challenges that have stood in the way of conducting such trials thus far.
Hmm.
Jenkins blamed the lapses on "long-standing limitations in staffing and information technology resources," saying that "competing workload priorities prevented us from the level of oversight and review of the entire portfolio of [postmarketing requirements] and [postmarketing commitments] that we would have desired …With new resources and congressional directives, FDA is committed to ensuring proper drafting and review of the entire portfolio going forward.”
Among the changes, each Center for Drug Evaluation and Research division now has a designated postmarketing study coordinator and a postmarketing study tracking coordinator.
In general, the deputy division director for safety - a position established under the agency's Safety First initiative - has assumed the postmarketing study coordinator job, and the safety regulatory manager will handle postmarketing study tracking. "These people as their full-time job are managing the safety and postmarketing study portfolio for their division," Jenkins said.
According to Jenkins, new policies and procedures are in place to "improve consistency in developing" postmarket requirements and commitments and lead to "better designed studies and trials with effective and realistic time frames for initial completion.” He added that other changes have been made to improved tracking and reviewing, including standardizing policies and procedures across CDER review divisions and offices.